Life Sciences Tools and Services
Company Overview of PureTech Health plc
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In ...
501 Boylston Street
Boston, MA 02116
Founded in 2015
Key Executives for PureTech Health plc
PureTech Health plc does not have any Key Executives recorded.
PureTech Health plc Key Developments
resTORbio, Inc. Begins Dosing Patients in the Second Part of Phase 2b Clinical Study
Nov 20 17
PureTech Health plc announced that resTORbio Inc. has begun dosing patients in the second part of a Phase 2b clinical study designed to assess the safety, tolerability and efficacy of resTORbio's lead programme in reducing respiratory tract infections (RTIs) in the elderly. This final stage of the study was initiated following a unanimous recommendation to proceed by the independent data monitoring committee overseeing the clinical study. resTORbio Inc. announced that an independent Data Monitoring Committee (DMC) has unanimously recommended advancing an ongoing Phase 2b clinical study to Part 2 of the study. The Phase 2b clinical study is a dose-range finding study of RTB101, an orally-administered TORC1 inhibitor, alone or in combination with everolimus as a first-in-class immunotherapy designed to enhance the ability of the aging immune system to fight infections. The Phase 2b clinical study is designed to assess the safety, tolerability and efficacy of 16 weeks of treatment with RTB101 alone or in combination with everolimus as compared to placebo in reducing the percentage of elderly individuals with respiratory tract infections (RTIs).
PureTech Health plc Presents at Jefferies 2017 London Healthcare Conference, Nov-16-2017 08:00 AM
Nov 9 17
PureTech Health plc Presents at Jefferies 2017 London Healthcare Conference, Nov-16-2017 08:00 AM. Venue: The Waldorf Hilton Hotel, Aldwych, London, United Kingdom. Speakers: Eric Elenko, Chief of Research and Strategy.
PureTech Health plc Announces an Exclusive Licensing Agreement with 3P Biotechnologies, Inc. for an Exosome-Based Technology
Sep 19 17
PureTech Health plc announced an exclusive licensing agreement with 3P Biotechnologies Inc. for an exosome-based technology (Calix) for the oral administration of biologics, nucleic acids, and complex small molecules. The Calix technology is based on the pioneering research of Ramesh Gupta, PhD, Founder of 3P Biotechnologies, Agnes Brown Duggan Chair in Oncological Research at the James Graham Brown Cancer Center, and Professor in the Department of Pharmacology and Toxicology at University of Louisville. This license, together with additional PureTech Health-generated intellectual property, establishes the company as a leader in the application of milk exosomes for the oral administration of therapeutic molecules. Exosomes, which contain mixtures of lipids, proteins and nucleic acids, play a critical physiologic role in intercellular communication and the transport of macromolecules between cells and tissues. Mammalian-derived exosomes have attractive potential as vehicles for the administration of a variety of drug payloads, especially nucleic acids, since their natural composition will likely provide superior tolerability over the variety of synthetic polymers currently in use. Previously, exosomes had not been considered viable as vehicles for oral administration of drugs due to their lack of stability under the harsh physiologic conditions associated with transit through the stomach and small intestine. However, the milk-derived exosomes that form the basis for the Calix technology have evolved specifically to accomplish the task of oral transport of complex biological molecules.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|